Iron supplements ‘don’t increase kids’ malaria risk’

Washington, July 8 (ANI): A new review by Cochrane Researchers suggests that iron supplements do not increase the likelihood of contracting malaria and should not be withheld from children at risk of the disease.

“Based on our review, children should not be denied iron supplements, even if they are living in areas where malaria is prevalent. Iron is important for growth and development, and maintaining a healthy immune system,” says lead researcher Juliana Ojukwu of the Department of Paediatrics at the Ebonyi State University in Ebonyi State, Nigeria.

Until 2007, World Health Organisation (WHO) guidelines recommended that all children should be given iron supplements to help prevent iron deficiency and anaemia, which are significant public health problems in developing countries. It is estimated that iron deficiency is the cause of 726,000 childhood deaths each year.

However, a recent large trial in Zanzibar prompted the WHO to change its guidelines, which now recommend that iron supplements are withheld from children under two years in areas where they are at high risk of contracting malaria.

The argument against giving iron is that it could help promote the growth of malarial parasites circulating in the blood.

In response to this, Cochrane researchers reviewed data from 68 different trials involving 42,981 children.

They concluded that iron did not increase the risk of malaria, as long as regular malaria surveillance and treatment services were available, and that there should not be any need to screen for anaemia before giving supplements.

They say WHO guidelines rely too heavily a single recent trial, whereas this current research drew its conclusions after giving appropriate weight to a wide range of studies.

Although the benefits of giving iron are greater for children with anaemia, any decision to withhold iron supplements should be carefully considered.

“Any potential negative effects of giving iron have to be weighed against the quite serious implications of not giving it, namely anaemia and its contribution to childhood infection and death, especially in Sub-Saharan Africa,” said Ojukwu. (ANI)

Blocking parasites in host cell may provide new way to fight malaria

Washington, Apr 4 (ANI): Researchers at the University of Pennsylvania have discovered a new way to fight malaria – locking the disease-causing parasite inside the host cells.

Led by Dr. Doron Greenbaum, Assistant Professor of Pharmacology in the Penn School of Medicine, the researchers found that parasites hijack host-cell proteins to ensure their survival and proliferation.

They found that malarial parasites depend upon an enzyme stolen from the host cell for successful infection, and thus paved the way for developing a new route of attack.

“Researchers can now develop ways to kill parasites by placing roadblocks in the path they use to destroy their victims,” said Greenbaum.

Starting with Plasmodium falciparum, which causes the most deadly form of human malaria, the researchers broadened their research to include Toxoplasma gondii, which causes a parasitic disease called toxoplasmosis.

Greenbaum said: “We always suspected that enzymes called proteases might be required to help parasites escape from the infected cell, but had assumed that these enzymes were produced by the parasites themselves. We had never considered that parasites might instead hijack host cell proteases. It’s an ingenious system. Our findings open up whole new window for drug discovery.”

As Plasmodium and Toxoplasma kill infected cells, they need to constantly hop from cell to cell to survive.

Scientists, however, still do not know what proteins the parasites use as tools to help them break through the walls of the cell.

To observe the behaviour of P. falciparum parasites, the research team infected human red blood cells, using pharmacological and biochemical evidence to discover that parasites activate the host protease calpain-1.

Blocking or removing calpain-1, a calcium-regulated protease, left parasites trapped inside the host cell. By adding calpain-1 back into the cell, parasites could once again blast free.

For knowing T. gondii’s behaviour, the researchers infected mouse fibroblasts with T. gondii and used genetic techniques to remove, and restore, calpain activity.

It was found that in the absence of calpain, parasites could not escape the infected cell, just as they had observed for malaria parasites.

The researchers concluded that targeting host proteins instead of the parasite itself might give the parasite less scope to develop resistance, since the parasite doesn’t have genetic control over host proteins.

Greenbaum is planning to continue exploring the viability of calpain as a drug target for antiparasitic drugs.

The study has been published in the online issue of the journal Science. (ANI)